meloxicam - Profile

What are the generic drug sources for meloxicam and what is the scope of patent protection?

Meloxicam is the generic ingredient in eight branded drugs marketed by Lupin Ltd, Novitium Pharma, Iceutica Operations, Baudax, Nanjing Delova, Azurity, Avondale Pharms, Tersera, Aiping Pharm Inc, Ascent Pharms Inc, Aurobindo Pharma, Chartwell Rx, Cipla, Corepharma, Cr Double Crane, Glenmark Pharms Ltd, Impax Labs Inc, Lupin Pharms, Mylan, Natco Pharma, Puracap Pharm, Rising, Roxane, Sun Pharm Inds Inc, Taro, Tp Anda Holdings, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, Boehringer Ingelheim, and Axsome, and is included in thirty-three NDAs. There are ninety patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Meloxicam has seventy-three patent family members in twenty-two countries.

Summary for meloxicam

International Patents:	73
US Patents:	90
Tradenames:	8
Applicants:	32
NDAs:	33
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for meloxicam

Paragraph IV (Patent) Challenges for MELOXICAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIVLODEX	Capsules	meloxicam	5 mg and 10 mg	207233	1	2017-01-09
MELOXICAM	Oral Suspension	meloxicam	7.5 mg/5 mL	021530	1	2009-12-17

US Patents and Regulatory Information for meloxicam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	MELOXICAM	meloxicam	CAPSULE;ORAL	209487-001	Jun 1, 2020	AB	RX	No	No
Lupin Ltd	MELOXICAM	meloxicam	CAPSULE;ORAL	209487-002	Jun 1, 2020	AB	RX	No	Yes
Novitium Pharma	MELOXICAM	meloxicam	CAPSULE;ORAL	211398-001	Mar 9, 2021	AB	RX	No	No
Novitium Pharma	MELOXICAM	meloxicam	CAPSULE;ORAL	211398-002	Mar 9, 2021	AB	RX	No	No
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No	9,808,468
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No	9,526,734		Y
Iceutica Operations	VIVLODEX	meloxicam	CAPSULE;ORAL	207233-001	Oct 22, 2015		DISCN	Yes	No	9,649,318		Y

Expired US Patents for meloxicam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020	10,463,673
Avondale Pharms	MELOXICAM	meloxicam	SUSPENSION;ORAL	021530-001	Jun 1, 2004	6,184,220*PED
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020	10,471,067
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020	8,512,727

EU/EMA Drug Approvals for meloxicam

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22
Boehringer Ingelheim Vetmedica GmbH	Novem	meloxicam	EMEA/V/C/000086Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.	Authorised	no	no	no	2004-03-02
Boehringer Ingelheim Vetmedica GmbH	Metacam	meloxicam	EMEA/V/C/000033Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.	Authorised	no	no	no	1998-01-07
Chanelle Pharmaceuticals Manufacturing Limited	Rheumocam	meloxicam	EMEA/V/C/000121DogsAlleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.CatsReduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.HorsesAlleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..For the relief of pain associated with equine colic.	Authorised	yes	no	no	2008-01-10
Emdoka bvba	Emdocam	meloxicam	EMEA/V/C/002283CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.	Authorised	yes	no	no	2011-08-18

International Patents for meloxicam

Country	Patent Number	Title	Estimated Expiration
Uruguay	36172	UNA FORMULACIÓN NOVEDOSA DE MELOXICAM
Singapore	11201610179Q	A NOVEL FORMULATION OF MELOXICAM
Japan	2012528171
Japan	6072539
Denmark	3090731
Canada	2951383	NOUVELLE FORMULATION DE MELOXICAM (A NOVEL FORMULATION OF MELOXICAM)
Eurasian Patent Organization	201692392	НОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА МЕЛОКСИКАМА

Meloxicam: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

This analysis examines the patent status and market fundamentals of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). Key patent expiries and generic competition impact market dynamics.

What is Meloxicam's Current Patent Status?

Meloxicam, a selective COX-2 inhibitor, is primarily marketed under brand names such as Mobic. Its foundational patents have largely expired in major markets, enabling widespread generic availability.

The original patent for meloxicam was filed in the late 1970s and early 1980s, with initial market approvals occurring in the early 1990s. For instance, its initial U.S. patent protection expired in the early 2000s [1]. Subsequent patents related to specific formulations, manufacturing processes, or new indications have been pursued by originator companies, but their impact on the core product’s market exclusivity has diminished significantly with the primary patent expirations.

Key patent expirations for Mobic (meloxicam) include:

• United States: The core composition of matter patent for meloxicam expired in 2019. While secondary patents for formulations or methods of use may exist, they do not block the generic entry of the active pharmaceutical ingredient (API) itself [2].
• Europe: Similar to the U.S., the primary patent protections for meloxicam have expired in key European markets, allowing for generic competition. Specific country patent expiry dates vary but generally fall within the first two decades of the 2000s.
• Other Major Markets: Expansions of patent protection in Canada, Japan, and Australia have also concluded, paving the way for generic versions in these regions.

The expiration of these foundational patents has led to a significant increase in the number of generic meloxicam products available globally. This shift from a branded, monopolistic market to a generic, competitive landscape fundamentally alters investment considerations.

What are the Market Dynamics for Meloxicam?

The market for meloxicam is characterized by mature sales, driven by its established efficacy and safety profile as an NSAID for treating osteoarthritis and rheumatoid arthritis. Genericization has led to price erosion and increased volume.

Market Size and Growth

The global NSAID market is substantial, with meloxicam occupying a significant segment within the non-opioid pain management sector.

• Global NSAID Market: Estimated at approximately USD 25 billion in 2022, with projections to reach USD 30 billion by 2028, exhibiting a compound annual growth rate (CAGR) of around 3-4% [3].
• Meloxicam Market Share: While specific meloxicam market share figures are not always publicly detailed due to its generic status, it is considered a leading NSAID globally. Analyst estimates place its annual sales in the hundreds of millions of U.S. dollars, with the majority of this revenue now coming from generic sales.

The growth in the NSAID market is driven by:

• Aging Population: Increased prevalence of degenerative joint diseases like osteoarthritis.
• Rising Incidence of Pain Conditions: Growing awareness and diagnosis of chronic pain.
• Shift from Opioids: Regulatory pressures and public health concerns are driving a move towards non-opioid analgesics like NSAIDs for pain management.

However, the growth for meloxicam specifically is tempered by:

• Intense Generic Competition: Leading to significant price reductions.
• Development of Newer Therapies: Advancements in biologic treatments for inflammatory conditions, though often at a higher price point and for more severe cases.

Competitive Landscape

The competitive landscape for meloxicam is dominated by generic manufacturers.

• Generic Manufacturers: Companies such as Teva Pharmaceutical Industries, Mylan (now Viatris), Aurobindo Pharma, and numerous others produce and market generic meloxicam [4]. The market is fragmented, with many players competing on price and distribution networks.
• Branded Product: Boehringer Ingelheim, the originator of Mobic, still maintains a presence but faces substantial competition from generics.

The competition primarily focuses on:

• Price: This is the most significant factor in the generic market.
• Supply Chain Reliability: Ensuring consistent availability of API and finished dosage forms.
• Geographic Reach: Distribution capabilities across different healthcare systems and countries.

Therapeutic Indications and Patient Population

Meloxicam is indicated for the symptomatic treatment of:

• Osteoarthritis (OA): The most common indication, involving chronic joint pain and inflammation.
• Rheumatoid Arthritis (RA): An autoimmune disease causing chronic inflammation of joints.
• Ankylosing Spondylitis (AS): A type of arthritis that affects the spine.

The patient population is broad, encompassing individuals suffering from chronic inflammatory and degenerative joint conditions, primarily in middle-aged and older adults. The prescription volume for meloxicam remains high due to its established role in managing these prevalent conditions.

What are the Investment Fundamentals for Meloxicam?

Investment in meloxicam is primarily within the generic pharmaceutical sector, focusing on manufacturing efficiency, supply chain management, and market access.

Manufacturing and Supply Chain

The production of meloxicam API and finished dosage forms is a critical investment consideration.

• API Sourcing: Meloxicam API is manufactured by several chemical synthesis companies globally, particularly in India and China, which offer cost-effective production [5]. Sourcing decisions depend on quality control, regulatory compliance, and cost.
• Manufacturing Costs: The cost of goods sold (COGS) for generic meloxicam is heavily influenced by raw material prices, labor costs, and economies of scale in manufacturing. Companies with efficient production processes and strong supplier relationships can achieve higher margins.
• Supply Chain Risks: Potential disruptions from geopolitical events, regulatory changes in manufacturing countries, or logistical challenges can impact supply availability and pricing. Diversifying sourcing and manufacturing locations can mitigate these risks.

Regulatory Environment

The regulatory landscape for pharmaceuticals, particularly generics, is stringent and requires continuous adherence.

• FDA and EMA Approval: Generic meloxicam products must obtain approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This involves demonstrating bioequivalence to the reference listed drug.
• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP standards, which are regularly inspected by regulatory agencies. Non-compliance can lead to product recalls, manufacturing halts, and significant financial penalties.
• Post-Market Surveillance: Ongoing monitoring for adverse events and product quality is required.

Market Access and Distribution

Securing market access and efficient distribution channels is vital for generic meloxicam sales.

• Payer Reimbursement: Insurance companies and national healthcare systems play a crucial role in determining formulary placement and reimbursement rates for generic drugs. Favorable formulary status can drive prescription volume.
• Pharmacy Chains and Wholesalers: Agreements with major pharmacy chains and drug wholesalers are essential for broad distribution.
• Tender Processes: In many countries, government tenders are a significant channel for bulk drug procurement, where pricing is highly competitive.

Financial Performance Indicators

Investment in meloxicam-focused companies involves analyzing standard financial metrics.

• Revenue Growth: While overall market growth for NSAIDs is moderate, revenue for specific generic meloxicam products may be influenced by pricing strategies, market penetration, and the number of competitors.
• Profit Margins: Generic drug margins are typically lower than branded drugs due to price competition. Companies with efficient operations can maintain healthy margins.
• Return on Investment (ROI): Evaluating ROI requires considering manufacturing investments, marketing expenses, and the long-term sales trajectory of generic meloxicam.

Key Takeaways

Meloxicam is a mature drug with expired foundational patents, leading to extensive generic competition. Investment opportunities lie within efficient generic manufacturing, robust supply chain management, and effective market access strategies. The market is driven by the aging population and the ongoing shift from opioid analgesics, but intense price competition and the emergence of newer therapies present ongoing challenges. Regulatory compliance and consistent quality are paramount for success.

FAQs

Is meloxicam still under patent protection in major markets?

No, the primary composition of matter patents for meloxicam expired in major markets such as the United States and Europe in the early to mid-2000s, allowing for widespread generic availability.

What are the main drivers of meloxicam market growth?

Key drivers include an aging global population, the increasing prevalence of chronic pain conditions like osteoarthritis and rheumatoid arthritis, and the ongoing healthcare trend to move away from opioid-based pain management towards non-opioid alternatives like NSAIDs.

What are the primary risks associated with investing in generic meloxicam manufacturing?

Primary risks include intense price competition among numerous generic manufacturers, potential supply chain disruptions due to global sourcing of APIs, stringent and evolving regulatory requirements, and pressure from payers for lower reimbursement rates.

How does the competitive landscape for meloxicam differ from that of a new drug launch?

The meloxicam market is characterized by a fragmented competitive landscape dominated by multiple generic manufacturers competing primarily on price and distribution efficiency. In contrast, a new drug launch typically begins with a period of market exclusivity for the innovator company, with competition gradually increasing as generics enter the market after patent expiry.

What is the typical profit margin for generic meloxicam?

Profit margins for generic meloxicam are generally lower compared to branded pharmaceuticals due to intense price competition. While specific margins vary by manufacturer and market, they often fall within the single to low double-digit percentage range, highly dependent on manufacturing costs and pricing strategies.

Citations

[1] U.S. Patent No. 4,233,452. (1980). Substituted 1,2-benzothiazine derivatives and their use as anti-inflammatory agents. Assignee: C.H. Boehringer Sohn.

[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA website data for meloxicam availability and patent status].

[3] Global Market Insights. (2023). Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market Size, Share & Trends Analysis Report.

[4] Various Generic Pharmaceutical Company Product Catalogs and Regulatory Filings. (Accessed 2023-2024).

[5] Market Research Reports on API Manufacturing in India and China. (Various Publishers, 2022-2023).